The field of interventional cardiology has undergone a phenomenal progression with remarkable device-specific innovations, which began with the introduction of metallic stents in the 90s. Medical researchers and scientists continue to burn the midnight oil to come up with innovative treatment procedures for curing artery diseases. As all eyes are focused on the next groundbreaking solution that will benefit cardiac patients, the China-based company, SINOMED, is all set to revolutionize cardiac care through its range of angioplasty devices that promise holistic healing.
SINOMED is a medical device company in the cardio and neurovascular space focused on marketing quality and innovative angioplasty devices that address unmet needs in the global market. SINOMED’s technology proficiency is brought through its understanding of the market needs.
One example of this is the BuMa Drug-Eluting Stent with bioabsorbable polymer that was developed to solve the persistent safety problems of stents. Most coronary stents used for angioplasty in the market are designed to minimize re-growth; in hopes of increasing the patency of the device. “We are, however, focused on providing a stent that encourages healing and delivers a healthier and safer solution for patients by decreasing long-term drug dependence and other problems,” explains Jianhua Sun, CEO, SINOMED.
BuMa is the company's first generation stent that is well proven and accepted in the market as an excellent performing device. Extensive clinical trials have been performed on this device in complex patients, proving it’s strong safety profile. The company is currently waiting for its next-gen drug-eluting stent—BuMa Supreme—to be launched in China, Europe, and APAC in 2020.
We are focused on providing a stent that encourages healing and delivers a healthier and safer solution for patients by decreasing long-term drug dependence
The new device will continue its healing approach, while improving its delivery system.
To combat the me-too product trap, where cardiology devices have become more like commodities, SINOMED strives to build innovation in everything they do. By understanding the root cause behind every complication in treating arteries, the company finds new solutions to unmet needs. “We concentrate more on the science, unlike some of the big players who have failed to identify the key issues as they are focused only on marketing,” says Sun. The uniqueness of the company lies in gathering insights from doctors who treat patients with coronary diseases and presenting them with solutions that tackle critical issues.
Being listed at the Shanghai STAR market has helped SINOMED raise a striking 350M RMB additional capital, which makes the company well-funded. Besides, the company recently completed the enrollment of a large scale randomized clinical study in the U.S. and Japan with more than 1600 patients. The study design was not only to demonstrate the benefits of their stents and its superiority but also to put across the message that their solutions would generate more safety benefits in the long-term for patients. “Our future investment is directed towards achieving additional benefits,” says Sun.
The SINOMED team is in lockstep with Sun in his pursuit of excellence and the vision of the company. The team is an ensemble of diverse minds working collaboratively and with utmost dedication to achieve the goals of the company.
The next five years for SINOMED looks bright as they plan to triple their capacity, with a focus on automating and vertical integration of all critical components of their products. To this end, Sun adds, “We want to establish our presence in the market as a company that raises the bar in interventional cardiology.”